2015 ACG ANNUAL SCIENTIFIC MEETING

Transcription

1 2015 ACG ANNUAL SCIENTIFIC MEETING Symposia Sessions, Special Lectures and Oral Abstract Presentations Program Description, Faculty Listing and Disclosure Information...8 Course Evaluation and CME Information...17 MONDAY MORNING, October 19, :25 am 11:40 am Simultaneous Symposia 1 Simultaneous Symposia 1A: Hepatitis C Update Moderator: Stanley M. Cohen, MD New Guideline-based Treatment Nancy S. Reau, MD Identify appropriate treatment regimens for specific hepatitis C populations. The Approach to the Treatment of the Complicated Hepatitis C Patient Paul Martin, MD, FACG Evaluate and successfully manage patients with decompensated cirrhosis, renal failure and coinfection. Navigating Hepatitis C Treatment in My Practice Stanley M. Cohen, MD Apply practical approaches to prior authorization, compliance and side effect management. Simultaneous Symposia 1B: Colonoscopy Quality in Practice: Fewer Mulligans, Next Steps After Failing to Make Par and Comparing Handicaps Moderator: Daivd M. Kastenberg, MD, FACG Improving Prep: Fewer Mulligans David M. Kastenberg, MD, FACG Describe grading systems for colonic preparations and identify practical strategies to optimize outcomes. Incomplete Colonoscopy: Next Steps After Failing to Make Par Joseph G. Cheatham, MD Compare and contrast alternate methods after technical failure of optical colonoscopy. How Do I Stack Up Against My Peers and Why Does This Matter? Comparing Handicaps David A. Johnson, MD, MACG Summarize the implications of individual reporting of colonoscopy quality metrics and strategies to improve the metrics. MONDAY AFTERNOON, October 19, :25 pm 2:10 pm The American Journal of Gastroenterology Lecture How Information Technology Will Transform Gastroenterology Brennan M. R. Spiegel, MD, MSHS, FACG Evaluate the impact that new technological innovations will have on patient care. Presentation files for the AJG Lecture will be made available to attendees during the meeting via the ACG 2015 app, as well as after the conclusion of the Annual Meeting. Please note: While evaluations for CME credit can ONLY be completed online (at information corresponding to the online evaluation is provided on page 17 to assist you in evaluating this course. 1

2 2:55 pm 4:10 pm Simultaneous Symposia 2 Simultaneous Symposia 2A: Preventing Problems and Treating Them as They Arise Moderator: Girish Mishra, MD, MSc, FACG Preventing Post-ERCP Pancreatitis Martin L. Freeman, MD, FACG Apply evidence-based strategies to reduce post-ercp pancreatitis via patient selection, endoscopic technique and pharmacologic intervention. Managing the Complications of Acute Pancreatitis: From Necrosis to Thrombosis Peter V. Draganov, MD, FACG Manage challenging complications of acute pancreatitis. Killing the Pain (But Not the Patient) in Chronic Pancreatitis Girish Mishra, MD, MSc, FACG Compare treatment methods for painful chronic pancreatitis. Simultaneous Symposia 2B: Inflammatory Bowel Disease Therapy: Making the Most of What We Have Moderator: William J. Tremaine, MD, FACG Corticosteroids and Thiopurines: Still Relevant to IBD in 2015? William J. Tremaine, MD, FACG Justify the use of cortisosteroids and thiopurines in the era of biologics. Good to the Last Drop: Optimizing Biologic Therapy in IBD Fernando S. Velayos, MD, MPH Calculate appropriate dosing regimens for biologic therapy. Generic Anti-tumor Necrosis Factor Therapy: Biosimilars Saints or Sinners? Gary R. Lichtenstein, MD, FACG Assess the impact of biosimilars on treatment regimens. Simultaneous Symposia 2C: Live from Honolulu! The 3rd Annual Endoscopy Video Forum Moderator: Seth A. Gross, MD, FACG Judges: Douglas G. Adler, MD, FACG, Carol A. Burke, MD, FACG, John R. Saltzman, MD, FACG, and Michael B. Wallace, MD, MPH, FACG See page 5 for listing information Tuesday morning, October 20, :30 am 9:00 am J. Edward Berk Distinguished Lecture Sleep Effect on GI Health and Disease: Eyes Wide Open? David A. Johnson, MD, MACG Interpret the data on sleep effects on gastrointestinal health and disease. 9:45 am 11:00 am Simultaneous Symposia 3 Simultaneous Symposia 3A: Evolving Concepts in the Treatment of IBS Moderator: William D. Chey, MD, FACG Probiotics and Antibiotics: Are These First-Line Agents? Mark Pimentel, MD, FACG Evaluate the clinical efficacy and safety of probiotics and antibiotics in IBS patients. Diet: Which Should You Choose for Your IBS Patient? William D. Chey, MD, FACG Assess dietary interventions in IBS using an evidence-based approach. 2

3 When Your Patient Wants a Pill: What Are the New and Upcoming Pharmacologic Options? Darren M. Brenner, MD Outline new treatments for IBS (eluxadoline, plecanatide, elobixibat, linaclotide) and upcoming therapies. Simultaneous Symposia 3B: The PPI Non-responsive Patient Moderator: John E. Pandolfino, MD, MSCI, FACG The Unresponsive and the Refractory Patient: What to Do and How to Manage John E. Pandolfino, MD, MSCI, FACG Use diagnostic tools to differentiate the unresponsive from the truly refractory GERD patient and outline the therapeutic options for these patients. The Functional GERD Patient (Visceral Hypersensitivity): Treatment Options Ronnie Fass, MD, FACG Assess the diagnostic criteria of functional GERD and visceral hypersensitivity and implement appropriate evidence-based medicine treatments. Diagnosis and Management of the Non-acid Reflux Patient Marcelo F. Vela, MD, MSCR, FACG Define the role of ph-impedance testing and the criteria for ineffective peristalsis and, identify the most appropriate treatments available for these conditions. Tuesday AFTERNOON, October 20, :15 pm 2:45 pm Emily Couric Memorial Lecture National Registry Benchmarking for Colonoscopy Quality: The High Road Toward Improving the Performance of Colonoscopy and Cancer Prevention Irving M. Pike, MD, FACG Appreciate the impact of measuring performance on improving GI endoscopic 2:45 pm 4:00 pm Simultaneous Symposia 4 Simultaneous Symposia 4A: The Sick Liver: Management of the Complications of Decompensated Cirrhosis Moderator: Mark W. Russo, MD, MPH, FACG The Bleeding Won t Stop: Portal Hypertensive Bleeding Mark W. Russo, MD, MPH, FACG Summarize appropriate management of portal hypertensive bleeding. I m Still Confused: Management of Hepatic Encephalopathy Beyond Lactulose Jasmohan S. Bajaj, MD, MSc, FACG Apply medical and dietary treatment alternatives to the patient who has encephalopathy and is not responding to lactulose. Cancer in the Liver: The Next Step Joseph Ahn, MD, MS, FACG Evaluate the multidisciplinary management of hepatocellular carcinoma. Simultaneous Symposia 4B: Controversies in the Management of Inflammatory Bowel Disease: Case Studies Moderator: Uma Mahadevan, MD, FACG The Use of Biologics as First-Line Therapy in the Treatment of IBD: One Size Fits All? Bruce E. Sands, MD, MS, FACG Select the appropriate patient to use biologic therapy as the first-line agent. 3

4 Doctor, Do I Have to Take This Medication Forever? Escalation and De-escalation of Therapy in IBD Uma Mahadevan, MD, FACG Assess how to alter dosing based on patient response. Continuing Immunosuppressive Therapy in the Patient With Infection or Malignancy Edward V. Loftus, Jr., MD, FACG Evaluate the risk of therapy in the setting of relative contraindications. Simultaneous Symposia 4C: CRE Infections in Endoscopy: What Happened and What Now? Moderator: David A. Greenwald, MD, FACG Duodenoscope Infections With CRE: What Happened? David A. Greenwald, MD, FACG Discuss duodenoscope infections with CRE. Infection Control and Safety In Endoscopy: Guidelines and Standards John A. Martin, MD Describe infection control and safety in endoscopy. Presentation files for Symposia 4C will be made available to attendees during the meeting via the ACG 2015 app, as well as after the conclusion of the Annual Meeting. CRE Related Infections in Endoscopy: What To Do Now? Douglas G. Adler, MD, FACG Identify ways to prevent CRE related infections in endoscopy. WEDNesday morning, October 21, :45 am 9:15 am David Y. Graham Lecture Eosinophilic Esophagitis 2015: From Acid Reflux to Food Allergy Ikuo Hirano, MD, FACG Recognize the importance of dietary factors in the pathogenesis and treatment of eosinophilic esophagitis. 9:30 am 10:45 am Simultaneous Symposia 5 Simultaneous Symposia 5A: Screening and Surveillance: Challenging Cases Apply the best evidence to common clinical conundrums in an interactive case-based discussion forum. Panelist: Aasma Shaukat, MD, MPH, FACG Panelist: Carol A. Burke, MD, FACG Panelist: Jason A. Dominitz, MD, MHS Simultaneous Symposia 5B: Endoscopic Ablation of Barrett s: How Far Have We Come? Moderator: Nicholas J. Shaheen, MD, MPH, FACG Ablation Therapies of Barrett s: To Freeze or to Burn the Dysplastic Barrett s Esophagus Patient and Its Role in Early Adenocarcinoma Nicholas J. Shaheen, MD, MPH, FACG Identify the benefits and limitations of RFA and cryotherapy for dysplastic Barrett s metaplasia and summarize surveillance protocols after eradication. When Is It Appropriate to Recommend Ablation for Non-Dysplastic Barrett s? Peter J. Kahrilas, MD, FACG Analyze the adverse outcomes, risks and benefits of ablation therapy in patients with low risk and non-dysplastic Barrett s metaplasia. Risk and Treatment of Persistent and Recurrent Barrett s Metaplasia: When to Stop and What to Do With the Buried Glands Kenneth K. Wang, MD, FACG Explain the approach to treat the dysplastic Barrett s esophagus and the practical endpoints with emphasis on persistent, recurrent Barrett s after ablation and buried glands. 4

5 ORAL ABSTRACT PRESENTATIONS Monday, October 19, 2015 Abstract Title 1. Diabetes Mellitus and Metabolic Syndrome: Independent Risk Factors for Hepatocellular 564 Carcinoma 2. Prognostic Impact of Achieving Sustained Viral Response in Patients With Hepatitis C After 565 Curative Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis 3. Rate, Risk Factors, and Outcomes of de novo Inflammatory Bowel Disease After Liver 567 Transplantation for Primary Sclerosing Cholangitis 4. Gut Microbiota Changes as Predictors of Treatment Failure in Primary Clostridium difficile Infection Associations of Clinical Symptoms and Bowel Characteristics With Intestinal Microbiota in Patients 568 With Irritable Bowel Syndrome 6. Impact of Histology Confirmation by GI Pathologist Panel on Progression Rates in Barrett s 569 Esophagus With Low-Grade Dysplasia: Results From a Multicenter Prospective BE Registry 7. Does Obesity Impact Mortality and Other Outcomes in Patients With Upper Gastrointestinal 570 Hemorrhage? A Nationwide Analysis 8. The Comparative Effectiveness of Upper Endoscopy and Angiographic Embolization in Achieving 571 Hemostasis for Recurrent Non-Variceal Upper Gastrointestinal Bleeding 9. Pancreatic Cancer in Urban African Americans: Too Young, Too Late! Effect of an Endoscopic Quality Improvement Program on Adenoma Detection Rates: A Multicenter 574 Cluster-Randomized Controlled Trial in Clinical Practice Setting (EQUIP-3) 11. Etiologies and Clinical Features of Nonresponsive Celiac Disease in Children Under the Age of Years 12. Endoscopic Evaluation and Associations With Clinical Manifestations of Acute Gastrointestinal 576 Graft-versus-Host Disease 13. Association of Aortic Valve Disease Associated With Bleeding Arteriovenous Malformations of the 578 Gastrointestinal Tract: Data From the Nationwide Inpatient Sample 14. Gastrointestinal Bleeding Among Mechanical Circulatory Support Devices Recipients: A Nationwide 580 Perspective 15. Gastric Intestinal Metaplasia in a U.S. Tertiary Care Population Gastric Cancer Detection by Novel Methylated DNA Markers: Tissue Validation in Patient Cohorts 581 From the United States and South Korea 17. The Diagnostic Performance of FDG PET/CT for Recurrent Gastric Cancer Is Significantly Affected 582 by Primary Tumor FDG Uptake Level 18. No Paper #18 Video 1. Endoscopic Removal of Gastric Band Using Stent-Induced Erosion Technique 583 Video 2. Large Gastric Conduit Dehiscence With Empyema Treated With Endoscopic Intervention 583 Video 3. GIST Cut It out Already! Successful Removal of an Exophytic GIST in the Gastric Cardia via 584 Endoscopic Full Thickness Resection Video 4. Endoscopic Closure of Gastric Defects Resulting From Endoscopic Full-thickness Resection by 584 Application of Novel Endoloops and Metallic Clips, Using Single-channel Endoscope: A Multicenter Study Video 5. Endoscopic Management of a Gastrocolonic Fistula: A Rare Esophageal Stent Adverse Event 586 Video 6. Endoscopic Needle-knife Stricturotomy in a UC Patient With Diverted Ileal Pouch and Anastomotic 586 Stricture Video 7. Underwater Resection of Colorectal Neoplasia: Taking the Plunge Into a New Technique 587 Video 8. A NOTES Approach to Acute Duodenal Perforation: A Minimally Invasive Approach Made Possible 588 by an Effective Endoscopic Suturing System Video 9. Transrectal Pure NOTES Cholecystolithotomy and Gallbladder Polypectomy With Gallbladder Preserved: The First Report on Human Cases 588 5

6 Tuesday, October 20, 2015 Abstract Title 19. A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor 589 Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study 20. First Trough Level of Infliximab at Week 2 Predicts Future Outcomes of Induction Therapy in 590 lcerative Colitis: A Post-hoc Analysis of a Multicenter Prospective Randomized Controlled Trial 21. Efficacy of Vedolizumab Maintenance Therapy With and Without Continued Immunosuppressant 591 Use in GEMINI 1 and GEMINI Fecal Calprotectin Levels Can Predict Pharmacokinetics of Anti-TNF Therapy Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential 593 Treatment Target in Patients With Small Bowel Crohn s Disease 24. Angiotensin II Blockade Is Associated With Worse Clinical Outcomes in IBD Patients Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients With 596 Inflammatory Bowel Disease 26. Visceral Transplantation for End Stage Crohn s Disease: 25 Years of Experience at a Single Center Temporary Fecal Diversion for Colonic and/or Perianal Crohn s Disease Does Active Technician Involvement During a Screening Colonoscopy Improve Physician Adenoma 599 Detection Rate? 29. Small Sessile Serrated Polyps Have Higher Rates of Advanced Adenomas Upon Surveillance Than 600 Small Tubular Adenomas 30. Screening Colonoscopy Withdrawal Time and Proximal Serrated Polyp Detection Rate: Analysis of a 600 Large, Single, High-Volume Center Using Natural Language Processing 31. G-EYE, High-Definition Colonoscopy Increases Adenoma Detection Rate Compared to Standard 602 High Definition Colonoscopy: Results of Prospective Randomized Multicenter Trial 32. Colorectal Cancer: Clinical Differences Among Hispanics and Non-Hispanic Whites: A Single 603 Institution s Experience Over 20 Years 33. Downregulation of Novel Tumor Suppressor Gene SA-1 in Early Colon Carcinogenesis Has a 603 Predilection for Blacks: Potential Biological Underpinnings for Colorectal Cancer (CRC) Disparities 34. Higher Rates of Advanced Histology in Small Adenomas Found on Surveillance After Colorectal 604 Cancer Resection Compared to Average-Risk Screening 35. No Paper # No Paper # Can the Use of Mesalamine Prevent Recurrent Diverticulitis? A Meta-analysis of Randomized 604 Controlled Trials 38. The Cost-Effectiveness of Competing Strategies for Managing Multiply Recurrent Clostridium 605 difficile Infection: Examining the Impact of Universal Stool Banks and Encapsulated Fecal Microbiota Transplantation 39. Predictors of Failure After Fecal Microbiota Transplantation (FMT) for the Therapy of Clostridium 607 difficile Infection (CDI) 40. Association of Chronic Constipation With Gastrointestinal Complications in Younger Patients Clinical Success of Colonic Stenting in Patients With Malignant Large Bowel Obstruction Due to 610 Extracolonic Malignancy 42. Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced 610 No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity 43. Accurate Identification of Excessive Methane Gas Producers by a Single Fasting Measurement of 611 Exhaled Methane: A Large-scale Database Analysis 44. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and 612 Safety of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection 45. No Paper # Impact of Recent Guidelines on the Role of EUS in Diagnosis of Asymptomatic Neoplastic 613 Pancreatic Cysts 47. Analytic Morphomics Accurately Distinguishes Serous and Mucinous Cystic Neoplasms 614 6

7 48. Utility of MicroRNAs in Differentiating Pancreatic Cancer and Autoimmune Pancreatitis Cost Effectiveness and Clinical Efficacy of Plastic vs Self-Expandable Metal Stents for Management 615 of Biliary Obstruction Due to Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy 50. Has Survival Improved Following Resection for Pancreatic Adenocarcinoma? Detection of Crohn s Disease in Patients With Spondyloarthropathies (SpA): A Prospective Capsule 616 Endoscopy-Based Study (SpACE Capsule Study) 52. Potential Risks of Immunosuppressant Drugs to the Pregnant Patient Colorectal Surgery in Inflammatory Bowel Disease (IBD)-Associated Colorectal Cancer (CRC) 617 Patients Has Worse Health Outcomes Than in Non-IBD Associated CRC Patients 54. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Ustekinumab, a Human Monoclonal Antibody to IL-12/23P40, in Patients With Moderately- to Severely-Active Crohn s Disease Who Are Naïve or not Refractory to Anti-TNFα: Results From the UNITI-2 Study 619 Wednesday, October 21, 2015 Abstract Title 55. Transepithelial Brush Biopsies With Computer-Assisted 3-Dimensional Analysis Markedly Improve Detection of Barrett s Esophagus and Dysplasia: Interim Analysis From a Prospective Multi-Center Community-Based Study 56. Low Bleeding Rates Associated With Esophageal Endoscopic Mucosal Resection for the Treatment of Dysplastic Barrett s Esophagus Octyl-Cyanoacrylate Injection for Acute Gastric Variceal Hemorrhage: 15-Year Experience of Outcomes and Predictors of Acute Rebleeding 58. IW-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, Improved Symptoms of Refractory GERD in a Double-blind, Placebo-controlled Phase 2a Study 59. Esophagogastric Junction Contractile Integral (EGJ-CI) Quantifies Changes in EGJ Barrier Function With Surgical Intervention 60. Assessment of Post-treatment Outcomes in Achalasia Utilizing Novel, High-Resolution Impedance Manometry Parameters 61. Endoscopic Submucosal Tunnel Dissection for Upper GI Submucosal Tumors Originating From the Muscularis Propria Layer: A Prospective Study 62. EUS Is Not Required for Staging Newly Diagnosed Malignant Esophageal Strictures That Preclude the Passage of a Standard Gastroscope: Results of a Prospective, Multicenter Study 63. Changing PPI Prescribing Patterns in the Wake of Recently Reported Adverse Effects: A Survey Study Comparing Gastroenterologists and General Practitioners 64. Discordant Liver Histology and NAFLD Fibrosis Scores in Morbidly Obese Bariatric Surgery Subjects 65. High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis 66. Acute Kidney Injury Among Hospitalized Patients With Alcoholic Liver Disease and Acute or Chronic Liver Failure 67. Sofosbuvir-Based Treatment Is Safe and Effective in Patients With Chronic Hepatitis C Infection and End-Stage Renal Disease 68. A Controlled Study of the Long-term Impact on Renal Function of Entecavir and Tenofovir Treatment for Chronic Hepatitis B 69. Does Cesarean Section and Formula Feeding Reduce Vertical Transmission in Chronic Hepatitis B Pregnant Mothers? 70. Early Use of TIPS and Outcomes in Patients With Cirrhosis and Acute Esophageal Variceal Bleeding: Analysis of the U.S. Nationwide Inpatient Sample (NIS) Database, The Utility of Repeat Diagnostic Paracentesis in the Management of Spontaneous Bacterial Peritonitis